Establishes an exception for small biotech manufacturers from Medicare drug price negotiations.

The Small Biotech Innovation Act amends the Social Security Act to create an exception for research and development-intensive small biotech manufacturers from the Medicare drug price negotiation program. This exception applies to manufacturers with 5 or fewer qualifying single-source drugs, with a tiered investment requirement in research and development. Manufacturers must submit annual applications and certify the accuracy of their submitted information.

Establishes an exception for small biotech manufacturers from Medicare drug price negotiations.

The Small Biotech Innovation Act amends the Social Security Act to create an exception for research and development-intensive small biotech manufacturers from the Medicare drug price negotiation program. This exception applies to manufacturers with 5 or fewer qualifying single-source drugs, with a tiered investment requirement in research and development. Manufacturers must submit annual applications and certify the accuracy of their submitted information.